December 29, 2025 a 09:00 am
DXCM: Analysts Ratings - DexCom, Inc.
DexCom, Inc. maintains a strong presence in the medical device market, with a focus on continuous glucose monitoring systems. Despite evolving market conditions, the company continues to secure robust ratings from analysts, reflecting confidence in its strategic positioning and product innovation.
Historical Stock Grades
| Rating | Number | Score |
|---|---|---|
| Strong Buy | 5 | |
| Buy | 20 | |
| Hold | 5 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
The historical data reveals a relatively stable analyst consensus over the months with a dominant 'Buy' rating. Stability in 'Strong Buy' ratings suggests significant market confidence. However, a slight increase in 'Hold' ratings indicates some caution among analysts.
- Overall ratings have remained stable with minor fluctuations.
- 'Strong Buy' ratings have decreased from 12 to 5 over the past year.
- Increased 'Hold' ratings signal growing caution among some analysts.
Percentage Trends
Despite a decrease in 'Strong Buy' ratings, DexCom, Inc. retains a majority of positive outlooks. The 'Buy' category remains strong, indicating enduring confidence. There is a modest shift towards more balanced evaluations, reflecting a thoughtful market perspective.
- 'Strong Buy' ratings decreased, suggesting a reassessment of market conditions.
- 'Buy' ratings hold steady, illustrating continued optimism in DexCom's prospects.
- 'Hold' ratings show a slight rise, indicative of increasing caution or volatility concerns.
- 'Strong Sell' and 'Sell' categories remain untouched, portraying inherent confidence in the stock.
Latest Analyst Recommendations
Recent analyst ratings for DexCom, Inc. demonstrate consistent confidence with minor shifts. Most analysts maintain their previous recommendations, reflecting steady conviction in the stock's potential.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-12-17 | Outperform | Outperform | Mizuho |
| 2025-12-11 | Buy | Buy | Citigroup |
| 2025-12-02 | Overweight | Equal Weight | Morgan Stanley |
| 2025-11-10 | Equal Weight | Equal Weight | Morgan Stanley |
| 2025-11-07 | Buy | Buy | Argus Research |
Analyst Recommendations with Change of Opinion
Changes in analyst opinions suggest nuanced shifts in market perspectives. Recent upgrades reflect growing optimism, balanced with occasional downgrades indicative of maturing market assessments.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-12-02 | Overweight | Equal Weight | Morgan Stanley |
| 2025-02-03 | Buy | Neutral | Redburn Atlantic |
| 2025-01-16 | Outperform | Neutral | Baird |
| 2024-07-26 | Neutral | Outperform | Baird |
| 2024-07-26 | Neutral | Overweight | JP Morgan |
Interpretation
The current analyst sentiment towards DexCom, Inc. suggests a balanced but positive outlook. With predominant 'Buy' ratings and stable 'Strong Buy' endorsements, the stock is perceived as a strong contender in the medical device industry. Analyst sentiment remains largely stable with few notable shifts, signaling sustained confidence with careful market consideration. Current market assessments reveal a sound foundation, but evolving market conditions warrant vigilant monitoring.
Conclusion
DexCom, Inc. remains a key player in the continuous glucose monitoring sector, benefiting from a stable and generally positive sentiment among analysts. While some shifts towards 'Hold' ratings suggest caution, the overall confidence supported by 'Strong Buy' and 'Buy' ratings reflects robust potential. The consistent upgrades indicate a shift to positive market expectations, but uncertainties in the wider economic landscape could influence future trends. Continued innovation and market expansion present substantial opportunities alongside inherent risks to monitor.